HealthchainStories
recist: Precision measurement for confident oncology care
The need
Cancer patients require periodic scans during their treatment to be able to adapt and monitor the therapy. Radiologists perform 4-5 imaging evaluations in a day, spending a lot of time interpreting the results, writing them in a descriptive/narrative way.
The main objective is to develop a digital solution to reduce the time for radiologist interpretation, increase the satisfaction of oncologists and radiologists for imaging results that will lead to better follow-up of patient journey for the management and decrease radiology subcontracting costs.
The HealthChain Support
HealthChain supported Healthcare Organisations in identifying their innovation challenges and selecting companies to address them. They worked closely as an interregional team to co-create, test, and validate a solution aligned with real clinical workflows, patient needs, and organisational constraints. The project provided financial and business support to boost the solution’s market-readiness and commercialisation.
The
Solution
To streamline and standardize radiological processes, Rayscape proposes a suite of oncology-focused AI algorithms. The core of the solution is a pilot platform that assists radiologists with lung nodule and mass analysis on both native and non-native computed tomography (CT) studies.
The platform integrates directly into existing clinical workflows and diagnostic tools, providing results in user-friendly, industry-compliant formats like secondary captures and SR reports.
The automated lung RECIST functionality serves as a strong differentiator against competitors, addressing the critical problem of overworked radiologists facing a global increase in medical imaging volume.
Impact
As a result of this successful implementation and the positive feedback gathered over two months of clinical use, the Rayscape RECIST extension has demonstrated clear value for several key stakeholders within the oncology ecosystem:
- Radiologists within the Healthcare Organization, who benefit from the automation of repetitive, mechanical measurements, allowing them to reclaim significant time previously spent on manual tasks.
- Hospital Management and Administrators, who gain increased diagnostic bandwidth; by saving time for medical professionals, the organization can process a higher volume of scans, ultimately driving operational efficiency and revenue growth.
- Oncologists at the Regional Level, who receive highly objective and standardised RECIST scores—driven by algorithmic precision—enabling a more accurate and consistent assessment of patient treatment response.
Outcomes
The pilot demonstrated significant improvements in efficiency and diagnostic quality:
- Successful integration of the RECIST extension within the live radiology workflows of Medisprof, proving the system’s compatibility with existing Healthcare Organization (HO) infrastructure.
- The tool was rigorously tested over two months of internal usage and further validated through external peer review by Key Opinion Leaders (KOLs) at the Romanian Congress of Radiology.
- By automating “tedious” manual measurements, the system allows radiologists to focus on higher-value tasks, lowering operational costs.
- Clinical studies on 440 images showed that AI assistance increased mean sensitivity for detecting suspect lung lesions from 73.9% to 81.7% (a 7.8% improvement).
- Surveys indicated an 87% satisfaction rate with Rayscape results and a 90% satisfaction rate specifically for the RECIST score.
- The project achieved 90% compliance with standardized report formats, measured through subjective feedback from HO users.
Sustainability
Rayscape has developed a comprehensive strategy to ensure the long-term viability of the solution and its expansion across the HealthChain regions:
- To ensure deep market penetration, the company is targeting its existing customer base—who already have a foundation of trust—using the Medisprof pilot as a primary “Customer Story” to provide evidence-based proof of impact.
- The RECIST feature is currently being integrated into the company’s medical device approval pathway, with specific focus on maintaining full compliance with the EU AI Act to ensure long-term legal and clinical viability.
- The RECIST criteria will become a part of Rayscape’s standard offering, with full integration expected by Q3 2026.
- The project has already generated significant commercial traction, with active engagements and future deployment plans established with 15 clinics across three countries and six regions, significantly exceeding original expansion targets.
Testimonials
